Specialisation
Retina and vitreous
Full title
An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravitreal injections to subjects with diabetic macular edema (DME)
Promoter
Bayer.
Start date
November 2016
End date
November 2019
Researchers
Main: Dr Anniken Burés.
